Abstract
<div>Abstract<p><b>Purpose:</b> This study aimed to understand the prognostic value of integrin β1 expression in head and neck squamous cell carcinoma (HNSCC) and the mechanism underlying its association with metastatic HNSCC.</p><p><b>Experimental Design:</b> Archival HNSCC tissues including 99 nonmetastatic primary tumors and 101 metastatic primary tumors were examined for the association of integrin β1 expression with metastasis and disease prognosis by appropriate statistical methods. Fluorescence-activated cell sorting was used to separate the integrin β1<sup>high/+</sup> cell population from the integrin β1<sup>low/−</sup> population in HNSCC cell lines. These two populations and integrin β1 shRNA knockdown HNSCC cells were examined for the effect of integrin β1 on invasion <i>in vitro</i> and on lymph node and lung metastases in a xenograft mouse model. Expression and activation of matrix metalloproteinases (MMP) were examined by zymography.</p><p><b>Results:</b> Statistical analysis showed that integrin β1 expression was significantly higher in the metastatic primary tumors than in the nonmetastatic tumors (42.6% vs. 24.8%, <i>P</i> < 0.0001 and <i>P</i> < 0.0001 by univariate and multivariate analyses, respectively). In patients with lymph node metastasis, integrin β1 expression was inversely correlated with overall survival (<i>P</i> = 0.035). The integrin β1 knockdown or integrin β1<sup>low/−</sup> HNSCC cells showed a significant reduction in lymph node and lung metastases <i>in vivo</i> (<i>P</i> < 0.001 and <i>P</i> < 0.05, respectively). Significantly reduced Matrigel invasion capability was also found in integrin β1 knockdown or integrin β1<sup>low/−</sup> HNSCC cells (<i>P</i> < 0.01). Finally, zymography results showed integrin β1-affected HNSCC invasion by regulating MMP-2 activation.</p><p><b>Conclusion:</b> These findings indicate that integrin β1 has a major impact on HNSCC prognosis through its regulation of metastasis. <i>Clin Cancer Res; 18(17); 4589–99. ©2012 AACR</i>.</p></div>
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.